HealthWell: Metabolic Dysfunction-Associated Steatohepatitis

Coverage RequiredNot Funded

About

The HealthWell Foundation MASH fund provides up to $8,000 per year in copay and premium assistance for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH). Wegovy received FDA approval for MASH with liver fibrosis in August 2025, making it eligible under this fund when prescribed for MASH indication. Income must be at or below 500% of FPL.

Insurance requirements: Commercially Insured, Medicare / Medicaid

Enrollment Forms

HealthWell Online Application

Benefits

•$8000 annual maximum benefit

Program Requirements

•Valid only for residents in the US and Puerto Rico

•Enrollment Required: Yes

•Coverage Required: Yes

•Needs Based: Yes

•Activation Required: No

Program Details

•Up to $8,000 per year in copay and premium reimbursement assistance

•No minimum copay or premium reimbursement amount

•Wegovy is eligible when prescribed for MASH indication (FDA approved August 2025)

•Income must be at or below 500% of Federal Poverty Level

•Must have insurance covering the medication and receive treatment in the US

•Patients must submit Diagnosis Verification form within 30 days

•Grants valid for one full year; must use or reenroll

•First reimbursement request must be within 90 days of approval

•Grants inactive for 90+ days will be closed

Enrollment Forms

HealthWell Online Application